AI illustration · not actual product photoDetails from the source.
Source-listed GHRP-6 Acetate (SKU G610): 10mg*10vials. PriceList(1).pdf lists 46 per 10 vials but does not specify currency; the website displays $46 per 10 vials in USD per owner instruction. The source row does not establish the supplier-specific item's identity, lot quality, or approval.
- Catalogue code
- G610
- Source specification
- 10mg*10vials
- Source document
- PriceList(1).pdf, page 2
- Photograph
- AI-generated illustration only — not an actual product photo or verified molecular depiction; owner-approved product photo still pending.
Product information is presented from supplied source materials. Inclusion on this website does not state that a product is an approved medicine or authorize human use. This is educational content, not medical advice.
Compound-level research and safety context.
Evidence below concerns the research family associated with this listing. For blends, findings about individual components do not establish evidence for the combination. This does not verify the supplier-specific vial or lot. Reviewed 2026-10-30.
What it is
The supplied catalogue lists the exact name ‘GHRP-6 Acetate’ for SKUs G65 and G610. Scientific literature describes GHRP-6 as a synthetic six-amino-acid peptide and growth-hormone secretagogue. The label does not verify the contents or acetate form of these specific vials. PriceList(1).pdf, page 2, lists G65 as *10vials at 25 per 10 vials, and G610 as *10vials at 46 per 10 vials; no currency is stated.
Biological mechanism
GHRP-6 acts through growth-hormone secretagogue receptor pathways, including GHS-R1a, engaging hypothalamic and pituitary regulation to stimulate growth-hormone release. Human challenge studies also report ACTH and cortisol responses, so the observed endocrine effects are not limited to growth hormone. [1] [2] [4]
Research focus
Human investigations have mainly examined short-term endocrine responses and pharmacokinetics. Laboratory and animal studies have explored additional cellular and cardiac effects, but these do not establish a human clinical application. [1] [2]
Potential applications in the evidence
Potential applications remain investigational. Studies have examined short-term growth-hormone secretagogue activity and endocrine testing/research; preclinical work has explored other effects. Evidence does not establish GHRP-6 as an effective treatment for a disease or health condition. [1] [2] [4]
Human evidence
Small controlled human studies show measurable growth-hormone responses and, in some populations, ACTH/cortisol responses. A pharmacokinetic clinical trial studied single exposure in nine healthy men. These limited studies do not establish long-term efficacy, sustained benefit, safety with repeated exposure, or outcomes for the catalogue-listed vials. [2] [4]
Known and potential effects
FDA notes that available safety-related information is limited and identifies potential cortisol effects and increased blood glucose associated with decreased insulin sensitivity for compounded drugs containing GHRP-6. Human challenge studies report ACTH/cortisol changes. FDA also raises potential immunogenicity risks for certain routes due to aggregation and peptide-related impurities. Frequency and clinical significance of harms are not adequately characterized. [2] [3] [4]
Safety and contraindications
Safety is not established for the exact product, formulation, contents, or route listed. FDA cites potential immunogenicity for certain routes and endocrine/metabolic concerns, including potential cortisol effects and increased blood glucose due to decreased insulin sensitivity. No reliable product-specific contraindication or interaction profile can be verified from the supplied label. [3] [4]
U.S. FDA / regulatory status
FDA lists GHRP-6 in Category 2 under interim 503B compounding policies because of potential significant safety risks. This is a compounding-policy risk designation, not FDA approval, and does not establish that the catalogue items are compounded. No FDA-approved GHRP-6 drug product was identified in the FDA material reviewed. The supplied catalogue lacks manufacturer, lot, formulation source, jurisdiction, and an approval identifier; the exact vial’s approval and regulatory status therefore cannot be verified. Approval or status of any active ingredient or other formulation must not be represented as transferring to these vials. [3]
Evidence limitations
Human evidence is sparse, short-term, and primarily pharmacologic rather than clinical-outcome research. Some findings come from specific disease populations or small studies. Animal/in-vitro findings do not demonstrate human benefit. The catalogue label and strength do not establish the vial’s actual identity, purity, sterility, formulation, route, or quality. [1] [2] [3] [4]
Supporting sources
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks U.S. Food and Drug Administration · Official FDA compounding safety/regulatory information. Supports: GHRP-6 Category 2 interim 503B compounding-policy listing and FDA-stated immunogenicity, cortisol, and glucose/insulin-sensitivity concerns; does not identify the catalogue item as compounded or approved.
- Synthetic Growth Hormone-Releasing Peptides Journal of Multidisciplinary Healthcare / PubMed Central · Peer-reviewed review. Supports: GHRP-6 peptide identity, secretagogue mechanism and context for limited human versus preclinical research.
- Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers European Journal of Pharmaceutical Sciences / PubMed, U.S. National Library of Medicine · Phase I clinical trial record and abstract. Supports: The limited single-exposure human pharmacokinetic evidence in nine healthy male volunteers.
- Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH Pituitary / PubMed, U.S. National Library of Medicine · Controlled clinical study record and abstract. Supports: Human endocrine challenge findings on GHRP-6 growth-hormone, ACTH, and cortisol responses in patients with Cushing's disease and controls.